Skip to main content
Pixium Vision logo

Pixium Vision — Investor Relations & Filings

Ticker · ALPIX ISIN · FR001400JX97 LEI · 96950046OPLRLKKEOO08 PA Manufacturing
Open in API
Filings indexed 440 across all filing types
Latest filing 2018-01-25 Regulatory Filings
Country FR France
Listing PA ALPIX

About Pixium Vision

https://www.pixium-vision.com/

Pixium Vision was a bioelectronics company that developed bionic vision systems to restore partial sight for patients with retinal diseases. Its core technology, the PRIMA System, is a photovoltaic subretinal implant designed to treat vision loss from advanced atrophic dry age-related macular degeneration (dry AMD). The system uses specialized glasses to project near-infrared light onto the implant, which converts the light into electrical signals to stimulate retinal cells and create a form of prosthetic vision. The company's assets, including the PRIMA technology and its ongoing European pivotal trial (PRIMAvera), were acquired by Science Corporation in late 2023. The trials and device manufacturing are now sponsored by La Science SAS.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated January 25, 2018, announcing a major operational milestone: the world's first successful activation of the PRIMA Bionic Vision System in a human subject for treating Atrophic Dry-AMD. It includes quotes from the CEO, the principal investigator, and the inventor, details about the clinical study, and contact information. This format—a news announcement detailing a significant event or result, often released outside of standard quarterly/annual reporting cycles—is characteristic of an Earnings Release (ER) if it contained financial results, or more generally, a Regulatory Filing (RNS) if it's a broad announcement. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change, and it is a formal announcement of a clinical/operational achievement, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if the company typically bundles such news with financial updates. Given the focus is purely on the clinical success and not financial performance highlights, RNS is the most appropriate general category for a significant, non-standard regulatory/operational update that doesn't fit the other specific codes. The document length (7854 chars) is substantial enough to be the primary document, not just a brief announcement of another report (ruling out RPA).
2018-01-25 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated January 4, 2018, announcing that Pixium Vision received FDA approval to begin a clinical study for its PRIMA implant. It details the purpose of the study, the CEO's comments, and provides background information on the technology and the company. This type of announcement, which is a specific, material corporate event update but not a full financial report (like 10-K or IR) or a standard earnings release (ER), fits best under the general category of Regulatory Filings (RNS) or potentially a specific announcement if one were available. Since it is a formal announcement of regulatory progress (FDA approval), and it is not a financial report, a management change, or a capital event, the most appropriate general classification for a significant, non-standard corporate update that isn't explicitly covered elsewhere is RNS (Regulatory Filings/General Announcement). It is not an Earnings Release (ER) as it discusses clinical trial progress, not financial results. It is not a Legal Proceedings Report (LTR) as it is a positive regulatory clearance, not a lawsuit update. Given the options, RNS serves as the best fit for a significant, non-financial, regulatory milestone announcement.
2018-01-04 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 96% confidence The document is a press release dated January 4, 2018, announcing that Pixium Vision received authorization from the US FDA to conduct a feasibility clinical study for its PRIMA subretinal implant in the US. It details the purpose of the study (evaluating tolerance and visual perception restoration) and the timeline. This type of announcement, which communicates a significant operational or regulatory milestone (like FDA approval for a trial), is typically classified as a general regulatory announcement or a corporate update that doesn't fit the specific financial report categories (10-K, IR, ER, etc.). Since it is a specific announcement about regulatory progress rather than a general regulatory filing fallback (RNS) or a specific financial report, and given the options, it most closely aligns with a general corporate announcement. However, none of the codes perfectly capture 'Regulatory Milestone Announcement' or 'Press Release'. Given the options, 'RNS' (Regulatory Filings - General regulatory announcements and fallback category for miscellaneous filings) is the most appropriate fit for a non-financial, non-management, non-legal, non-dividend, non-capital structure specific corporate news release concerning regulatory progress, especially when compared against the other specific codes.
2018-01-04 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 98% confidence The document is a press release dated January 3, 2018, titled "Information relative au nombre total de droits de vote et d'actions composant le capital social au 31 décembre 2017" (Information relative to the total number of voting rights and shares comprising the share capital as of December 31, 2017). This content specifically details the total number of voting rights and shares outstanding as of a specific date, which is a mandatory periodic disclosure related to the company's capital structure. This type of announcement, which reports on changes or status updates to the share capital or voting rights, aligns best with the 'Share Issue/Capital Change' category (SHA). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). Since it is a direct announcement about the capital structure count, SHA is the most precise fit.
2018-01-03 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Transaction in Own Shares Classification · 95% confidence The document is titled "Bilan annuel du contrat de liquidité Pixium Vision contracté avec la Société de Bourse Gilbert Dupont" (Annual balance of the liquidity contract...). It reports the status of a liquidity contract (stock held and cash balance) as of December 31, 2017, comparing it to the previous semi-annual balance (June 30, 2017). This type of regular update concerning market making or liquidity provision, especially when presented as a formal balance sheet update, often falls under specific regulatory reporting or general investor relations updates. Since it is a periodic report detailing the status of a specific financial arrangement (liquidity contract) rather than a full financial statement (10-K or IR), and it is not a standard earnings release (ER) or management discussion (MDA), it best fits the category for updates related to capital structure or financing activities, or potentially a general regulatory filing. Given the context of reporting on a specific financial arrangement (liquidity contract), it is most closely related to Capital/Financing Update (CAP) or a general Regulatory Filing (RNS). However, liquidity contracts are often disclosed as part of ongoing obligations. Since it is a specific, periodic report on a financial arrangement, and not a general announcement of a report, I will classify it as a Capital/Financing Update (CAP) as it relates directly to the management of the company's stock availability/market support, which is a financing/capital mechanism. If a more specific category existed for 'Liquidity Contract Update', that would be chosen. Lacking that, CAP is the closest fit among the provided options for a specific financial mechanism update.
2018-01-03 French
Share buybacks / Liquidity contracts Information related to liquidity contracts
Regulatory Filings Classification · 99% confidence The document is titled "Full year update on Pixium Vision's liquidity agreement with Gilbert Dupont" and provides specific figures (share count and cash amount) held in a liquidity account as of December 31, 2017, compared to June 30, 2017. This type of announcement, detailing the status of a market-making or liquidity provision agreement, is a specific corporate action announcement. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS). It relates to the company's capital structure maintenance or market support activities. Given the options, it most closely relates to financing/capital activities or a specific regulatory disclosure that isn't covered by the main categories. Since it is a specific update on a financial arrangement (liquidity agreement), and not a general capital raise (CAP) or share transaction (POS), it fits best under the general 'Regulatory Filings' (RNS) as a specific, non-standard disclosure, or potentially 'Capital/Financing Update' (CAP) if the liquidity agreement is viewed broadly as a financing mechanism. However, liquidity agreement updates are often treated as specific market disclosures. Given the lack of a specific code for 'Liquidity Agreement Update', and since it is a formal, dated announcement, RNS (Regulatory Filings) is the most appropriate fallback for a specific, non-core financial disclosure that doesn't fit the other precise categories like DIV, ER, or 10-K. The document length is short (4167 chars), but it is the primary content, not an announcement *of* another report.
2018-01-03 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.